- The disease
- Conductive hearing loss occurs when sound cannot pass efficiently through the outer or middle ear, while mixed hearing loss involves both a conductive component and damage to the inner ear or auditory nerve. These conditions can result from chronic ear infections, malformation of the ear canal or ossicles, or prior surgery. Conventional hearing aids may be unsuitable for patients with chronic ear discharge or structural abnormalities, making bone conduction devices an alternative pathway for sound delivery.
- What the asset is trying to do
- The Osia 2 System is an active osseointegrated implant that converts sound into vibrations and transmits them directly through the skull bone to the inner ear, bypassing the outer and middle ear. Unlike passive bone conduction systems, the Osia 2 uses an integrated piezoelectric actuator implanted under the skin, which Cochlear describes as delivering vibrations without a percutaneous abutment (per Cochlear product documentation). The external sound processor communicates wirelessly with the implant through the intact skin.
- What the trial is measuring, and why it matters
- The completed clinical studies listed in the trial registry assessed clinical performance, safety, and patient-reported outcomes for the Osia 2 System across adult and paediatric populations (per ClinicalTrials.gov NCT04041700, NCT05000931). The NCT04320407 study was described as a CPT Code Study, relating to procedural coding for reimbursement purposes in the United States (per ClinicalTrials.gov NCT04320407). Outcome measures in bone conduction device studies commonly include aided hearing thresholds and speech recognition scores, though the specific endpoints for each trial are not detailed in the data provided.
- Efficacy benchmarks in this setting
- Regulatory approval benchmarks for bone conduction hearing devices in the United States are set by the FDA, which cleared the Osia 2 System. For context on the broader treatment setting, conventional bone-anchored hearing aids (BAHAs) such as the Cochlear Baha 5 and Oticon Medical Ponto systems have been evaluated in clinical studies; for example, the Baha Attract System study by Briggs et al. (Otology and Neurotology, 2015) reported mean aided free-field thresholds and speech recognition improvements, though specific figures from that study are not reproduced here. Direct numerical comparison between different bone conduction device studies is limited by differences in patient populations, audiological criteria, and outcome measurement methods; figures from the Osia 2 trials listed above are not statistically comparable to those from other device studies without review of the primary publications.